At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Pfizer presented preliminary data from the Phase III TALAPRO-3 clinical trial, which is evaluating the poly(ADP-ribose) polymerase (PARP) inhibitor Talzenna (talazoparib) in combination with Xtandi (enzalutamide), a standard androgen receptor signaling inhibitor (ARSI). This dual-action regimen is specifically designed for patients with metastatic castration-sensitive prostate cancer (mCSPC) harboring homologous recombination repair (HRR) gene mutations. Treatment of advanced prostate cancer is shifting toward early precision medicine, a more personalized treatment regimen that takes into account a patient's molecular and biomarker profiles.
Preliminary results from a phase III clinical trial showed that talazoparib in combination with enzalutamide demonstrated a favorable trend in overall survival (OS) compared with enzalutamide in combination with placebo. Importantly, the primary endpoint data demonstrated a clinically meaningful improvement in radiographic progression-free survival (rPFS) in patients with metastatic prostate cancer with DNA repair gene (HRR) mutations compared with enzalutamide in combination with placebo, with a 52% reduction in the risk of progression and death. Furthermore, when assessing rPFS in patients with BRCA gene mutations (BRCAm) compared with patients with other DNA repair gene mutations (non-BRCAm), both groups benefited from combination therapy. A 63% risk reduction was observed in the BRCAm group, and a 43% risk reduction was observed in the non-BRCAm group. By improving rPFS, this treatment may lead to the wider use of combination therapy in the treatment of metastatic prostate cancer. This may also influence how physicians choose treatment sequences, particularly for patients who are candidates for both hormonal therapy and targeted therapy. This study also highlights the importance of molecular biomarker testing in prostate cancer, which could allow some patients in the early stages to receive more effective treatment and improve their prognosis.
Finally, on June 1, 2026, Foundation Medicine announced FDA approval for FoundationOne CDx and FoundationOne Liquid CDx in combination with Talzenna and Xtandi. This is a significant development, as many prostate cancer patients could benefit from accurate diagnosis and effective, simplified treatment.
The article "ASCO26: Talzenna and Xtandi combination shows promising results as first-line therapy for metastatic prostate cancer with altered HRR" was originally created and published by Pharmaceutical Technology, a brand owned by GlobalData.
The information on this website is provided in good faith and is for general informational purposes only. It is not intended to constitute advice on which you should rely, and we make no representations, warranties, or promises, express or implied, regarding its accuracy or completeness. Before making or refraining from making any decisions based on the information provided on our website, you should seek professional or specialized advice.